Boston Trust Walden Corp Sells 8,171 Shares of Edwards Lifesciences Corporation $EW

Boston Trust Walden Corp decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,905 shares of the medical research company’s stock after selling 8,171 shares during the period. Boston Trust Walden Corp’s holdings in Edwards Lifesciences were worth $22,754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. True Wealth Design LLC increased its stake in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares in the last quarter. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Finally, Dorato Capital Management bought a new stake in Edwards Lifesciences in the fourth quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $81.47 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $69.84 and a fifty-two week high of $87.89. The stock has a market cap of $46.97 billion, a price-to-earnings ratio of 44.52, a PEG ratio of 2.08 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm’s 50-day simple moving average is $81.47 and its 200 day simple moving average is $82.17.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the firm posted $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on EW. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $95.74.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.